Study wrapper · #147
Erratum.
Editor's note
This item is an erratum correcting the results section of a previously published conference abstract on GLP-1 receptor agonist use in children and young people with severe obesity across 35 English specialist clinics; the original abstract was based on a preliminary dataset, and this correction reports updated figures. As corrected, 406 young people (mean age 15.3) on semaglutide were matched to 787 comparators, and %BMIp95 was lower in the semaglutide group by 13.8, 19.0 and 22.9 percentage points at 6, 12 and 18 months (relative reductions of roughly 9 to 14%). Treat this with real caution: it is a corrected conference abstract, not a peer-reviewed full paper, in a matched (non-randomized) pediatric cohort with a high burden of comorbidity, so confounding and adherence are unaddressed here. Weight it as an early, real-world observational signal in an especially vulnerable population where evidence is thin, pending full peer-reviewed publication.
Plain-language abstract
This is a correction to an earlier conference summary about using GLP-1 medicines in children and teenagers with very severe obesity, treated at 35 specialist weight-management clinics in England. The original summary used a preliminary dataset, and the authors have now published updated numbers. In the corrected version, 406 young people (average age about 15) taking semaglutide were matched to 787 similar patients not taking it. The group had many obesity-related health problems, including fatty liver disease, blood-sugar problems, sleep apnea, and high rates of depression or anxiety. Compared with the matched group, those on semaglutide had lower obesity measures at 6, 12, and 18 months, with the gap widening over time to about a 14% relative reduction in one measure and around 11% in BMI by 18 months. Because this is a corrected conference summary in a matched, non-randomized group, it should be viewed as early real-world data rather than firm evidence.